<DOC>
	<DOC>NCT02985957</DOC>
	<brief_summary>The purpose of this study is to determine whether nivolumab plus ipilimumab has preliminary evidence of safety and effectiveness in treatment of metastatic castration-resistant prostate cancer</brief_summary>
	<brief_title>A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Metastatic, castrate resistant prostate cancer (M1 by National Comprehensive Cancer Network (NCCN) criteria) Eastern Cooperative Oncology Group (ECOG) performance status 01 Ongoing androgen deprivation therapy (ADT) with a Gonadotropinreleasing hormone (GnRH) analogue or a surgical/medical castration with testosterone level of ≤1.73nmol/L (50ng/dL) Patients with skeletal system symptoms who are already on medications to strengthen bones are allowed if they were started ˃28 days before enrollment Bonedirected radiotherapy to pelvic region for ease of pain from painful bone metastases is allowed up to 14 days before Cancer that has spread to the liver or brain Active, known, or suspected autoimmune disease or infection Prior treatment with any drug that targets T cell costimulation pathways(such as checkpoint inhibitors) Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>